Rheumatoid arthritis (RA) is a systemic autoimmune disease that affects joints, especially synovial joints, with symmetric arthritis as the main clinical manifestation, and is a very disabling and common chronic arthritis with an incidence of 0.3% to 0.5%. If not given early and effective treatment, it seriously affects the joint function and quality of life of patients, traditional treatment aims to reduce pain, but the side effects are large, and it is difficult to inhibit joint destruction, deformation and dysfunction. There are still no reports of reversal of bone destruction in RA in the literature at home and abroad. Since September 2006, our department has applied a long course of Yunque to treat 15 patients with advanced rheumatoid arthritis, multiple joint bone erosion and severe dysfunction with remarkable results. 15 patients were hospitalized in our department, and all of them met the diagnostic criteria of rheumatoid arthritis revised by the American Rheumatism Association in 1987. Thirteen patients were female and two were male, aged 21-81 years, with a history of rheumatoid disease ranging from 7 to 40 years, and all had severe polyarticular pain, bone erosion, and varying degrees of joint dysfunction and muscle atrophy. Among them, 7 cases were bedridden and could not eat on their own, and 8 cases could do but could not stand or walk. All 15 patients had a history of multiple medications, including various NSAIDs, penicillamine, chloroquine, methotrexate, leucovorin, zhengqing, pavoline, salbutamol, tumor necrosis factor antagonist, ant powder, bee venom, etc. All 15 patients were on long-term glucocorticoid maintenance therapy, including 6 patients on dexamethasone and 9 patients on prednisone. The shortest duration was 6 months and the longest was 16 years. Case presentation: Female, 46 years old, with recurrent joint swelling and pain with morning stiffness of the extremities for 10 years, had been treated with chloroquine, methotrexate, rheumatism, Zhengqing wind pain, pavoline, hormone, ant powder, bee venom local seal, etc., but the symptoms were sometimes relieved, but the joint deformation was very serious and the functional activities were increasingly restricted. He had been taking oral prednisone and methotrexate for 9 months. Pre-existing history: allergic, allergic to all non-steroidal anti-inflammatory drugs. The main manifestations of the joints of the extremities were: multi-joint: temporomandibular joint pressure pain, restricted mouth opening, bilateral shoulder joint pressure pain, range of motion only 5 degrees to 15 degrees, bilateral elbow, bilateral wrist, metacarpophalangeal joint swelling and pressure pain, bilateral elbow can not be straightened, 100 degrees to 120 degrees, bilateral wrist can not be flexed, both hands finger joint deformation, can not clench fist, can not be straightened, bilateral knee joint pressure pain, swelling, the right knee is heavy, 145 degrees of flexion, multi-joint Muscle atrophy. Laboratory tests showed only hemoglobin 6.0g/L, platelets 460×1012/L, rheumatoid factor 640 reactive protein 96Iu/ml, sedimentation 138 mm/h, and no other abnormalities. X-rays showed typical rheumatoid arthritis changes in both hands, wrists, shoulders and knees, with obvious narrowing of both wrists and knees, joint erosion, irregularity, local soft tissue swelling, obvious muscle atrophy, showing generalized osteoporosis, and proximal interphalangeal joints of both hands with subluxation. The patient was treated with Yunker in December 2006, and was given prednisone 10mg/day and methotrexate 15mg/week orally. 1 week later, the joint swelling and pain decreased, the range of motion of the shoulder joint increased, the knee joint improved, and he ate on his own. 2 weeks later, the joint swelling and pain further decreased, the hands were strong, and he could wash his face and stand on his own for a few minutes. 4 weeks later, the joint movement improved significantly, and although the knee joint could not be completely straightened, he could walk with crutches. After 8 weeks, the joint pain disappeared, there was no joint pain, and the patient could walk on his own. 10 weeks later, the patient could walk up and down stairs and live on his own. Prednisone was gradually discontinued after 8 months of treatment. The patient had hemoglobin 8.0g/L, platelets 260×1012/L, rheumatoid factor 160 Iu/ml, reactive protein 12Iu/ml, and sedimentation 48 mm/h in 3 months of treatment, and hemoglobin 10.0g/L, platelets 190×1012/L, rheumatoid factor 40 reactive protein 5Iu/ml, and sedimentation 28 mm/h in 1 year of treatment, and the remaining complete blood analysis X-rays showed no abnormal changes in joint soft tissue swelling, osteoporosis improved, joint erosion did not improve significantly, and bone gap did not change. 1 year later, joint osteoporosis improved significantly, joint surface was clearer than before, joint erosion improved to varying degrees, with the most obvious improvement in both hands, and bone gap widening was not obvious. The patient has resumed work and is confident in her life as she rides a bicycle to and from work every day. RA is an inflammatory autoimmune disease that mainly involves peripheral joints. Without systematic treatment, the disability rate is higher than 15%, and the disease can occur at any age with a very high disability rate. It is one of the main causes of labor loss and disability in the population. It seriously endangers the physical and mental health of patients. Although there are many drugs for the treatment of RA, they are not effective and have high side effects, cannot control the disease and have a high recurrence rate. In recent years, commonly used therapeutic drugs such as NSAIDs, corticosteroids (hormones), immunosuppressants and various Chinese medicinal preparations have made some progress in relieving the clinical symptoms of various osteoarthritic diseases, but their prognosis is still unsatisfactory. While biologics are gradually being used in China, their toxic side effects, unpredictable risks and high costs make it difficult to promote them on a large scale. People are still eagerly waiting for some new therapeutic drugs with ideal efficacy, less toxic side effects and cheaper price. In recent years, the clinical application of Yunque for RA treatment has shown that it can significantly relieve joint pain, reduce joint swelling and morning stiffness, and also reduce laboratory indicators related to the acute inflammatory response, such as hematocrit, C-reactive protein and platelets. This in turn reduced synovial inflammation in a rat model of collagen-induced arthritis. MDP is a salt compound that has good targeting to osteoarthritic and synovial tissues and can correct osteoporosis by reducing osteoclast activity and inhibiting bone resorption. Secondly, MDP also has high affinity for metal ions and can chelate zinc and calcium ions in the center of matrix metalloproteinases, reducing matrix metalloproteinases (such as collagenase activity) and preventing the catabolic destructive effect of collagenases on cartilage tissues. In vitro experiments have also found that Yunque inhibits osteoclast activity and promotes osteoblast division and new bone formation. The basic and clinical research on the treatment of RA with YUNK is still in progress. The efficacy of Yunque in the treatment of RA is obvious, with low adverse effects and safe use. As a new type of anti-rheumatic drug, it is worth promoting because it has anti-inflammatory and analgesic effects, and also has the effect of DMARDs to improve the disease.